NCT00577421

Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO

An Extension Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Warner Chilcott · Industry
• Sex: Female
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, RVE1998080, and RVE2001079 (NCT01249261)

Detailed description

A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, RVE1998080, and RVE2001079 (NCT01249261)

Conditions

• Postmenopausal Osteoporosis

Interventions

Type	Name	Description
DRUG	risedronate	5 mg tablet of risedronate once a day for 2 years

Timeline

• Start date: 2003-06-01
• Completion: 2006-01-01
• First posted: 2007-12-20
• Last updated: 2011-09-28

Locations

5 sites across 5 countries: Australia, Italy, Poland, Spain, Sweden